J. Yi

发表

Overcoming soluble target interference in an anti-therapeutic antibody screening assay for an antibody-drug conjugate therapeutic.

M. Carrasco-Triguero, K. Hong, S. Kaur, 2012, Bioanalysis.

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.

D. Miles, J. O’Shaughnessy, V. Diéras, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine.

Surinder Kaur, Montserrat Carrasco-Triguero, Zhihua Julia Qiu, 2013, Bioanalysis.

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Suzanne F. Jones, M. Sliwkowski, M. Beeram, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability.

S. Girish, J. Beyer, J. Tibbitts, 2013, Toxicology and applied pharmacology.

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Dan Lu, Amita Joshi, Patricia M. LoRusso, 2012, Cancer Chemotherapy and Pharmacology.

Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates

M. Cobleigh, S. Girish, P. Conte, 2014, Cancer Chemotherapy and Pharmacology.

An Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling in Patients with HER2-Positive Metastatic Breast Cancer

H. Burris, S. Girish, I. Krop, 2013, Clinical Pharmacokinetics.

Effects of Trastuzumab Emtansine (T‐DM1) on QT Interval and Safety of Pertuzumab Plus T‐DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

P. LoRusso, S. Girish, A. Joshi, 2013, Clinical pharmacology in drug development.

Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2‐Targeted Antibody‐Drug Conjugate, in Patients With HER2‐Positive Metastatic Breast Cancer

P. LoRusso, M. Beeram, S. Girish, 2012, Journal of clinical pharmacology.

PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine.

Jakub Baudys, Randall C Dere, Ola M. Saad, 2013, Bioanalysis.

A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans

Brian H Annex, T. Henry, S. Ellis, 2002, Clinical pharmacology and therapeutics.

Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer.

H. Burris, S. Girish, J. Cortés, 2012, Current drug metabolism.

Population Pharmacokinetics of Trastuzumab-DM1, a First-in-Class HER2 Antibody-Drug Conjugate Given Every 3 Weeks (q3w) and Weekly (qw) to Patients with HER2-Positive Metastatic Breast Cancer (MBC).

P. LoRusso, M. Beeram, S. Girish, 2009 .

P1-12-07: Pharmacokinetics (PK) of Trastuzumab Emtansine and Paclitaxel or Docetaxel in Patients with HER2−Positive MBC Previously Treated with a Trastuzumab-Containing Regimen.

S. Girish, A. Elias, S. Modi, 2011 .

Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2‐Targeted Antibody‐Drug Conjugate, in Patients With HER2‐Positive Metastatic Breast Cancer

P. LoRusso, M. Beeram, S. Girish, 2012, Journal of clinical pharmacology.